Device Trial Radar · NCT04801771
Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
57
Actual
Start
Jun 24, 2021
Primary completion
Jul 1, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Inspire Medical Systems, Inc.Public (INSP)
- Sponsor type
- Industry
- Collaborators
- National Institutes of Health (NIH); National Institute on Deafness and Other Communication Disorders (NIDCD)
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 10 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
Conditions
- Down Syndrome
- Obstructive Sleep Apnea
Interventions
Inspire Upper Airway Stimulation (UAS) SystemDevice
The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2)Time frame: 6 Months post-implant
- Change in attention using the Wechsler Intelligence ScaleTime frame: 6 Months post-implant
- Change in processing speed using the Cambridge Neuropsychological Test Automated Battery (CANTAB)Time frame: 6 Months post-implant
3 more outcomes with a free account
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Children's Healthcare of Atlanta/ Emory University School of Medicine
Atlanta, Georgia
Massachusetts General Hospital (Mass Eye & Ear Infirmary)
Boston, Massachusetts
Cincinnati Childrens Hospital
Cincinnati, Ohio
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.